Multiple Sclerosis Clinical Trial
An Extension of the TG1101-RMS201 Trial
Summary
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Eligibility Criteria
Inclusion Criteria:
Subjects currently enrolled in TG1101-RMS201 trial
Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled assessments up to the final 48-week visit
Exclusion Criteria:
Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101- RMS201 study during the 48-week evaluation period
Subjects who have started any other immunomodulating or disease modifying therapy after completion of the TG1101-RMS201 trial
Pregnant or nursing mothers
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Pasadena California, 91105, United States
Aurora Colorado, 80045, United States
Lexington Kentucky, 40513, United States
Columbus Ohio, 43210, United States
Westerville Ohio, 43081, United States
Knoxville Tennessee, 37922, United States
Round Rock Texas, 78681, United States
San Antonio Texas, 78258, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.